Last reviewed · How we verify

Polyethoxylated Sorbitan Monooleate (POLYSORBATE 80)

FDA-approved active Small molecule Quality 16/100

POLYSORBATE 80, a marketed polyethoxylated sorbitan monooleate, is positioned in the redness relief segment of the ophthalmic market. Its key strength lies in its mechanism of action, which reduces the surface tension of tears to promote an even distribution and maintenance of a healthy tear film. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic namePOLYSORBATE 80
ModalitySmall molecule
Therapeutic areaOphthalmology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: